Proteasome inhibitor MG-132 induces MCPIP1 expression

Area of Science:

• Cell Biology
• Molecular Biology
• Biochemistry

Background:

• The proteasome degrades polyubiquitin-tagged proteins and regulates gene transcription.
• Monocyte chemotactic protein-1 induced protein 1 (MCPIP1) is involved in cellular processes.
• Understanding proteasome function is crucial for cancer therapy.

Purpose of the Study:

• To investigate the effect of proteasome inhibition on MCPIP1 expression.
• To elucidate the mechanisms underlying MCPIP1 upregulation by proteasome inhibitors.
• To explore the role of MCPIP1 in proteasome inhibitor-induced cell death.

Main Methods:

• Treatment of HepG2 and HeLa cells with proteasome inhibitor MG-132.
• Analysis of MCPIP1 mRNA and protein levels.
• Assessment of MCPIP1 stability and de novo mRNA synthesis.
• Inhibition of specific signaling pathways (ERK1/2, p38).
• Cell viability assays and apoptosis detection (caspase 3/7 activation).

Main Results:

• Proteasome inhibition by MG-132 significantly increased MCPIP1 mRNA and protein levels.
• MG-132 did not affect MCPIP1 stability but induced de novo mRNA synthesis.
• Extracellular-signal-regulated kinase 1/2 and p38 kinases mediated MG-132-induced MCPIP1 upregulation.
• MCPIP1 overexpression decreased HeLa cell viability and sensitized them to MG-132.
• Both MG-132 treatment and MCPIP1 overexpression activated apoptosis.

Conclusions:

• Proteasome inhibition impacts MCPIP1 expression through modulation of intracellular signaling pathways.
• MCPIP1 upregulation contributes to the toxicity of proteasome inhibitors.
• This study reveals a novel link between proteasome function, MCPIP1, and apoptosis in cancer cells.